



**SAVE THE DATE**

*Announcement*

# CAN CON UPDATES 2024



**SATURDAY, 26 OCTOBER 2024**  
12:00 PM TO 7:30 PM ONWARDS



**SUNDAY, 27 OCTOBER 2024**  
9:00 AM TO 1:15 PM ONWARDS



**VENUE**  
HOTEL ALOFT, AEROCITY, NEW DELHI



## **Dr. Samit Purohit**

MBBS, MD, DM (Medical Oncology), Hematology & BMT Expert,  
Director, Department of Medical Oncology & Hematology,  
Action Cancer Hospital Paschim Vihar, New Delhi



Event Managed By  
**AMDGLOBALNET**  
amdglobalnet.com

**UNDER THE AEGIS OF**  
Society on promotion Activation & Research  
For Scientific Social Helps (SPARSSH)  
95, 3rd Floor, Wazir Nagar, Kotla Mubarakpur,  
New Delhi-110003

 **+91 9319311009**

 **sparssh.org**

# TENTATIVE AGENDA

Day 1 - 26th October 2024

| TIME               | TOPIC  | FACULTY   |
|--------------------|--|---|
| 12:00 NOON Onwards | Registration   |   |
| 1:00-2:00 PM       | LUNCH  |   |
| 2:00 - 2:05 PM     | Welcome & Context Setting  | DR SAMIT PUROHIT  |
|                    | Chairperson  | Dr Rakesh Chopra /Dr Manoj Sharma                             |
| 2:05-2-15 pm       | OPTIMIZING THE USE OF SBRT IN LUNG CANCER. Special Session   | DR DODUL MONDAL   |
| <b>SESSION 1</b>   | <b>Session 1 : GI-HEPATOBILIARY</b>  |   |
| 2:15-2:30 pm       | WHAT CAN WE GET OUT OF A COMPREHENSIVE GENOMIC PROFILING REPORT ?  | DR SHILPA PATIL   |
| 2:30-2:24 pm       | ROLE OF HIPEC IN GI CANCER.  | DR NIKHIL GUPTA   |
| 2:45-3:00PM        | NEWER UPDATES IN THE MANAGEMENT OF 1ST LINE ADVANCED BILIARY TRACT CANCERS.  | DR SANDEEP TIWARI   |
| 3:00 -3:20 PM      | Pembrolizumab in the management of MSI-HdMMR Advanced- CRC,A new Therapeutic Benchmark in Immuno-Oncology.           | DR ANKIT BATRA  |
| <b>SESSION 2</b>   | <b>Session 2 : Lung Cancer</b>   |   |
|                    | Chairperson  | Dr GK Jadhav /Dr Viny Kantroo                                 |
| 3:20-3:40 PM       | Revolutionizing care-Going beyond boundaries in ES SCLC.   | DR Sunil Kumar Gupta  |
| 3:40-3:45 PM       | EXPERT COMMENTS Q&A  |   |
| 3:45-4:00 PM       | Optimizing treatment decision in Unresectable Stage III NSCLC_A case Study   | DR KUMARDEEP DUTTA  |
| 4:00-4:15 PM       | Reinventing AdjuvAnt Therapy in EGfem early Lung Cancer.   | DR TARUN DURGA  |
| 4:15-4:30 PM       | Why I choose Osimertinib as first choice in advanced lung cancer vs other targeted treatment ?                       | DR PARVEEN JAIN   |
| 4:30-4:45 PM       | Optimizing the management of advanced EGFRm NSCLC with chemotherapy combinations                                     | DR ANKIT JAIN   |
| 4:45-5:05 PM       | Novel treatment option in Lung Cancer with Focus on Pembrolizumab  | DR MRIDULL MALHOTRA   |
| 5:05-5:35 PM       | Panel discussion- Integrating IO in management of Early Lung cancer- The oncologist's role in multidisciplinary care | CHAIRPERSON<br>DR KULDEEP SHARMA                              |
|                    | MODERATOR  | DR MANISH SINGHAL   |
|                    | PANELISTS  | DR ADITYA VIDHUSHI  |
|                    |  | DR VIKAS CHOUDHARY  |
|                    |  | DR BABITA   |
|                    |  | DR MOHIT SAXENA   |
|                    |  | DR SANJEEV KUMAR  |
|                    |  | DR SAHIL BAMBROO  |
| 5:35-5:50 PM       | MEETING UNMET NEED IN PATIENTS WITH MET EX-14 SKIPPING NSCLC.  | DR PEUSH BAJPAI   |
| 5:50:-6:30 PM      | Breaking Frontiers in 1L mNSCLC: Leveraging anti PD -1 & Anti CTLA-4 for high Unmet need Patients.                   |   |
|                    | MODERATOR  | Dr Chandragauda   |
|                    | PANELISTS  | Dr Ankur Punia/Dr Pooja Gupta/Dr Saurabh Mishra/Dr Tanvi Sood |
| 6:30-7:00 PM       | A NEW BENCHMARK IN FIRST LINE MANAGEMENT OF ALK-REARRANGED NSCLC .   | DR PARVEEN JAIN/DR ABHISHEK RAJ/DR MUKESH PATEKAR             |
| 7:00-7:15 PM       | TEA BREAK  |   |
|                    | Chairperson  | DR SHISHIR AGGRWAL/Dr SVS Dev/Dr Arun Giri                    |
| <b>SESSION 3</b>   | <b>Session 3 : Breast Cancer</b>   |   |
| 7:15-7:30 PM       | ART OF RECONSTRUCTION IN BREAST CANCER   | DR HIMANSHU   |
| 7:30-7:50 PM       | TNBC- Role of Immunotherapy and it's Sequencing Strategy Advanced TNBC   | DR MOHIT AGARWAL  |
| 7:50-8:05 PM       | IMPACT OF SUBCUTANEOUS DUAL BLOCKAGE IN Her2+ Breast Cancer. PHESGO  | DR PANKAJ GOYEL   |
| 8:05-8:15 PM       | FDC-IN BREAST CANCER: COMCAPSY   | DR NIKHIL HIMTANI   |
| 8:15 PM            | VOTE OF THANKS AND FOLLOWED BY DINNER  | DR SAMIT PUROHIT/DR SUSHANT                                   |

# TENTATIVE AGENDA

Day 2 - 27th October 2024

| TIME              | TOPIC  | FACULTY                                    |
|-------------------|--|--|
| 9:00 AM           | REGISTRATION   |  |
| 9:30-10:00 AM     | Breakfast & Networking   |  |
|                   | SPOTLIGHT -SESSION   |  |
| 10:00-10:15 AM    | ROLE of PICC-Line in Oncology.<br>SESSION SPONSORED BY : BARD INDIA                                | DR RAVINDER                                |
| <b>SESSION 4</b>  | <b>Session 4 : HEAD &amp; NECK CANCER</b>  |  |
|                   | Chairpersons:  | Dr. KAPIL KUMAR<br>Dr. H P YADAV           |
| 10:15-10:30 AM    | NIMOTUZUMAB IN ADVANCED H/N CANCER   | DR PANKAJ GOYEL                            |
| 10:30-10:45 AM    | Response or Survival or both in Recurrent and /or<br>Metastatic Head & Neck Cancer.                | DR ASMITA JAIN                             |
| 10:45-11:00 AM    | THE NEW HORIZON IN MANAGEMENT OF NPC.  | DR NEHA                                    |
| 11:00-11:20 AM    | HNSCC- Role of IO and it's Sequencing Strategy in the<br>management of HNSCC                       | DR ABHISHEK SINGH                          |
| <b>SESSION 5</b>  | <b>Session 5 : G-U CANCER</b>  |  |
|                   | Chairpersons:  | DR RUPINDER SHEKHON / DR<br>SUSHANT MITTAL |
| 11:20-11:30 AM    | MSI in Endometrial Cancer.   | DR SHRUTI BHATIA                           |
| 11:30 AM-12:00 PM | PARP INHIBITORS IN OVARIAN CANCER  | DR BHUSHAN THOMBARE                        |
|                   | MODERATOR  | DR NAGENDER SHARMA                         |
|                   | PANELIST   | DR SAURABH MISHRA                          |
|                   |  | DR ABHISHEK SINGH                          |
|                   |  | DR AMIT PANDEY                             |
|                   |  | DR AVINASH PANDEY                          |
|                   | <b>Session 6 : HEAMATOLOGY</b>   |  |
| <b>SESSION 6</b>  | <b>Chairpersons:</b>   | <b>Dr Shishir Seth</b>                     |
| 12:00-12:20       | REVOLUTIONISING TREATMENT OF cHL WITH FOCUS ON<br>Immunotherapy.                                   | DR TRIBIKRAM PANDA                         |
| 12:20-12:35 PM    | TECLISTAMAB-A NEW KID ON BLOCK FOR MM.   | DR CHITRESH YADAV                          |
| 12:35-12:50 PM    | POLIVY ( Polatuzumab Vedotin ) in previously untreated<br>Diffuse Large B- Cell Lymphoma ( DLBCL). | DR SUSHANT MITTAL                          |
| 12:50-1:15 PM     | CAR-T CELL- HOPE OR HYPE.  | DR AMRITA RAMASWAMY                        |
| 1:15 PM           | VOTES OF THANKS -LUNCH   | DR SAMIT PUROHIT                           |

# OUR ACADEMIC PARTNERS



Johnson & Johnson



# Thank You

